Aug 10, 2021 4:04pm EDT CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 10, 2021 4:02pm EDT CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity
Aug 04, 2021 4:05pm EDT CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021
Jul 14, 2021 9:00am EDT CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity
May 17, 2021 4:02pm EDT CohBar Reports First Quarter 2021 Financial Results and Provides Business Update
May 03, 2021 9:00am EDT CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021
Apr 27, 2021 8:30am EDT CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director
Apr 21, 2021 9:00am EDT CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity